Kailera nets $600m to power Phase III launch of obesity drug
Just a year after emerging from stealth with a nearly half a billion dollars, Kailera Therapeutics has reached another financing…
Metabolic Disorders
-
-
Novo Nordisk buys MASH specialist Akero for up to $5.2bn
Novo Nordisk has agreed to buy Akero Therapeutics in a deal rising to a potential $5.2bn, as the Danish drugmaker…
-
Can oral GLP-1RAs deliver on the promise of accessible obesity care?
As the race for oral glucagon-like peptide-1 receptor agonists (GLP-1RA) intensifies, physicians hope that their small molecule format will make…
-
Pfizer buys monthly GLP-1RA developer Metsera for $4.9bn
Pfizer has acquired Metsera for $4.9bn, as the drugmaker targets longer-lasting glucagon-like peptide-1 receptor agonists (GLP-1RAs) to cement market share…
-
Sanofi’s Tzield gains approval in China for T1D management
China’s National Medical Products Administration (NMPA) has approved Sanofi’s Tzield (teplizumab), making it the first disease-modifying therapy for autoimmune type…
-
Novo’s Ozempic price cut expected to slow market share erosion
Novo Nordisk’s decision to significantly reduce the price of blockbuster drug semaglutide is expected to slow the shift of patients…
-
WHO adds GLP-1RAs to essential medicines list
The World Health Organisation (WHO) has updated its model list of essential medicines (EML) to include four key obesity and…
-
EMA warns of rise in illegal weight loss drugs marketed online
The European Medicines Agency (EMA) has warned of a sharp rise in illegal medicines being sold under the guise of…
-
Chinese drugmakers prep for looming semaglutide generics horizon
Chinese pharmaceutical companies are eyeing a lucrative commercial market set to materialise upon the patent expiry for Novo Nordisk’s blockbuster…
-
Novo Nordisk enlists srRNA developer Replicate in $550m deal
Novo Nordisk has turned to Replicate Bioscience’s RNA drug platform in a lucrative research collaboration, marking the latest effort by…
